ABSTRACT OBJECTIVES This study sought to investigate the clinical outcomes based on the assessment of quantitative coronary angiography-maximal lumen diameter (Dmax).
. Another matter of concern is the risk of scaffold disruption (9) , particularly when the device has already reached its maximal limit of expansion and is overexpanded in an attempt to correct persistent malapposition. Conversely, an OCT substudy showed an excess of proximal and/or distal edge dissections when the Absorb scaffold was implanted in vessels smaller than the device nominal size (8) . However, the impact of quantitative angiographic guidance on clinical outcomes is so far unknown. Therefore, the aim of this study was to investigate the relationship between clinical outcomes and maximal diameter (Dmax) by QCA, which was used as a guide for appropriate selection and deployment of the Absorb scaffold in 2 cohorts of patients from the ABSORB Cohort B study, ABSORB EXTEND study, and ABSORB II trial.
METHODS STUDY DESIGN AND POPULATION.
We analyzed the results of Absorb scaffold implantation in 1, 248 patients enrolled between 2009 and 2013 in the ABSORB Cohort B study (2, 4) , ABSORB EXTEND study (7) , and ABSORB II (1) randomized controlled trial.
The design of each study is described elsewhere (4, 6, 7, 10) . In the ABSORB Cohort B, a 3.0 Â 18-mm Absorb scaffold only was available. In the ABSORB EXTEND and ABSORB II studies, patients were treated as follows (1,7): 1) a 3.5-mm Absorb scaffold was used when both the proximal and distal Dmax were within an upper limit of 3.8 mm and a lower limit of 3.0 mm: 2) a 3.0-mm Absorb scaffold was used when both the proximal and distal maximal lumen diameters were within an upper limit of 3.3 mm and a lower limit of 2.5 mm: 3) a 2.5-mm Absorb scaffold was used when both the proximal and the distal Dmax were within an upper limit of 3.0 mm and a lower limit of 2.25 mm: and 4) scaffold overlap was allowed. Patients demographic data and baseline characteristics were similar among 3 studies as well as pre-procedure minimal lumen diameter (MLD) and % diameter stenosis. All of these trials were sponsored and funded by Abbott Vascular. The research ethics committee of each participating institution approved the protocol, and all enrolled patients provided written informed consent before inclusion.
STUDY DEVICE. The details of the study device (Absorb, Abbott Vascular, Santa Clara, California) have been described in detail previously (5, 6) . In brief, the balloon-expandable Absorb scaffold comprises a poly-L-lactide backbone (6) coated with an amorphous drug-eluting coating matrix composed of poly-D,L-lactide polymer containing everolimus.
QCA ANALYSIS. QCA guidance of Absorb implantation relies on the angiographic diameter function curve of the pre-treatment vessel segment that contains 3 nonambiguous data points; namely, the MLD and the Dmax with respect to the MLD of the proximal (proximal Dmax) and distal (distal Dmax) vessel segments of interest (8, 11) (Figure 1) . QCA analyses were undertaken by the sites before Absorb implantation, and post-procedurally by an independent core laboratory (Cardialysis BV, Rotterdam, the Netherlands) using a Coronary Angiography Analysis System (Pie Medical Imaging, Maastricht, the Netherlands).
DEFINITIONS AND ENDPOINTS.
The patient population in the present study was stratified by the difference between the angiographic maximal diameter Ishibashi et al.
and the nominal diameter of the implanted scaffold.
The selection of device size was considered "over- In the present analysis, the primary clinical outcome assessed was ischemia-driven major adverse cardiac events (ID-MACE), defined as a composite of cardiac death, any myocardial infarction (MI classified as Q-wave or non-Q-wave MI), and ischemia-driven target lesion revascularization (ID-TLR) by coronary artery bypass graft or percutaneous coronary intervention. Cardiac death was defined as any death due to a proximate cardiac cause (e.g., MI, low-output failure, fatal arrhythmia). The method used to measure proximal and distal Dmax with QCA is shown. In the pre-procedural angiography (A), the operator has to define the landing zone where the scaffold will be implanted (B). Within the landing zone, the peak of the diameter function curve proximal to the minimal lumen diameter is defined as proximal (P) Dmax (C), whereas the peak diameter function curve distal (D) to the minimal lumen diameter is defined as distal Dmax (D). In this case, the proximal and distal Dmax of 2.83 and 2.96 mm led to the correct sizing of the Absorb (3.0 mm) with regard to the vessel diameter (E). DMAXD ¼ maximal lumen diameter distal; DMAXP ¼ maximal lumen diameter proximal; MLD ¼ minimal lumen diameter; QCA ¼ quantitative coronary angiography; RVD ¼ reference vessel diameter.
Relation Between Bioresorbable Scaffold Sizing and Clinical Outcomes elevated creatine kinase-myocardial band levels in the absence of new pathological Q waves (12) . STATISTICAL ANALYSIS. All analyses were conducted using the intention-to-treat population. For the The graph represents the proximal Dmax value, the distal Dmax value and the nominal size of the implanted Absorb scaffold(s) in 1,232 patients. The Dmax measurement is based on core lab assessment. According to the manufacturer, the 2.5-mm, 3.0-mm, and 3.5-mm scaffolds cannot be dilated beyond their nominal size of 3.0 mm, 3.5 mm, and 4.0 mm, respectively. The limit of expansion of the scaffold is depicted by a green continuous line. Theoretically, dotted red areas indicate implantation of a too "small" Absorb scaffold in a relatively large vessel, and dotted orange areas indicate implantation of a too "large" Absorb scaffold in a relatively small vessel. Device size selection with regard to Dmax was considered appropriate in 867 (70.4%) patients and inappropriate in 365 (29.6%) patients. Dmax ¼ maximal lumen diameter.
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RESULTS
Of a total population of 1,248 patients, pre-procedural Dmax was assessed by the core laboratory in 1,232
(98.7 %) patients. Clinical and angiographic characteristics between the scaffold oversize group and the scaffold nonoversize group are detailed in Table 1 . The 2 groups did not significantly differ with regard to main baseline clinical characteristics, whereas pre-procedural MLD, reference vessel diameter, and both proximal and distal Dmax were significantly smaller in the scaffold oversize group than in the scaffold nonoversize group.
The scaffold oversize group was associated with a higher risk of ID-MACE than the scaffold nonoversize group. As illustrated in Figure 3 , the graphical presentation clearly shows that a higher number of these patients can be seen in the lower left quadrant (scaffold oversize group) than in the other quadrants of the graph (6.6% vs. 3.3%, p < 0.01). MACE occurred in 46 of 760 patients when a relatively large device size was selected, whereas it occurred in 16 of 472 patients when a relatively small device size was selected (6.1% vs. 3.4%, p ¼ 0.04).
The MACE and MI rates at 1 year and 2 years were significantly higher in the scaffold oversize group Values are mean AE SD, or % (n). Clinical and pre-and post-procedural angiographic characteristics are according to the distribution of Dmax measurements minus the nominal scaffold size in the scaffold oversize group versus the scaffold nonoversize group.
ACC/AHA ¼ American College of Cardiology/American Heart Association lesion characteristics; Dmax ¼ maximal lumen diameter; RVD ¼ reference vessel diameter; TIMI ¼ Thrombolysis In Myocardial Infarction.
6.6% vs. 3.3%; log-rank p < 0.01, 2-year MACE: 8.7% vs. 5.9%; log-rank p ¼ 0.03, 1-year TVMI: 4.5% vs. events. In the scaffold oversize group, PMI occurred in 64% (18 cases), whereas in the scaffold nonoversize group, the PMI rate was 35.7% (10 cases). There were no statistically significant differences in the incidence of overall angiographic complications that could be documented at the end of the procedure for patients who had TVMI within 1 month (3.1% vs. 1.7%; p ¼ 0.14) ( Table 3 ). The incidence of ST tended to be higher in the scaffold oversize group than in the scaffold nonoversize group ( Table 3 ). A case of a definite early ST is shown in Figure 5 .
When the appropriateness of scaffold size was defined by nominal scaffold diameter within 0.5 mm Distribution of proximal and distal Dmax measurements minus nominal scaffold size in patients with or without major adverse cardiac events is shown. When the appropriateness of scaffold size was defined by nominal scaffold diameter within 0.5 mm of Dmax, the differences between the distal Dmax and nominal scaffold size are plotted on the y-axis and x-axis, respectively. The red filled circles represent the patients who experienced ID-MACE at 1 year. The graphical presentation demonstrates that major adverse cardiac events (MACE) were more frequently observed in patients in whom both proximal and distal Dmax were smaller than the device nominal size (6.6% vs. 3.3%, p < 0.01) (lower left quadrant). Dmax ¼ maximal lumen diameter; ID-MACE ¼ ischemia-driven major adverse cardiac event(s). Table 4) .
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DISCUSSION
The main findings of this study are: 1) 52.7% (n ¼ 649) of patients had an "oversize" scaffold implantation;
2) The MACE and MI rates at 1 year were significantly higher in the scaffold oversize group than in the scaffold nonoversize group (MACE: 6.6% vs. 3.3%, log-rank p < 0.01, all MI: 4.6% vs. 2.4%; log-rank p ¼ 0.04), mainly driven by a higher rate of MI within 1 month after the procedure (3.5% vs. 1.9%; p ¼ 0.08); the incidence of definite ST tended to be higher in the scaffold oversize group than in the scaffold nonoversize group (1.54% vs. 0.51%,OR: 3.03
[0.83 to 11.05]; p ¼ 0.10); 3) The independent determinants of MACE were both Dmax smaller than the device nominal size (OR: 2.13, 95% CI: 1.22 to 3.70;
FIGURE 4 Time-to-Event Curves of MACE and Its Components
Time-to-event curves of MACE (A) and its components (B: death, C: target vessel MI; D: ID-TLR) at 2 years, according to study group. ID-TLR ¼ ischemia-driven target lesion revascularization; MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction.
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1.17 to 3.80; p ¼ 0.01).
As illustrated in the scaffold oversize group in Values are % (n).
Abbreviations as in Table 2 . Ishibashi et al.
nominal size is associated with a higher risk of ID-MACE (6.6% vs. 3.3%; p < 0.01). The difference in 1-year MACE was observed in the scaffold oversize group and was mainly driven by a higher MI rate (4.5% vs. 2.1%; p < 0.01). Scaffold expansion below nominal diameters can lead to a denser polymer surface pattern and a higher polymer-toartery ratio (Online Figure 3) . Furthermore, the expanding radial force may be suboptimal in these underdeployed configurations; presumably, these unfavorable final expansion diameters might cause micro thrombus formation at the strut level and side-branch occlusion. However, no statistically significant difference in the incidence of overall angiographic complications could be documented at the end of the procedure for the patients who sustained MI within 1 month (scaffold oversize group: 3.1% vs. scaffold nonoversize group: 1.7%; p ¼ 0.14) ( Table 3) .
With multivariable logistic regression analysis, the independent determinants of 1-year MACE were: implantation of an Absorb scaffold(s) in a vessel with both proximal and distal Dmax smaller than device nominal size (OR: 2.13, 95% CI: 1.22 to 3.70; p < 0.01) and overlapping scaffolds (OR: 2.10, 95% CI: 1.17 to 3.80; p ¼ 0.01) ( Table 4) . Of note, in a juvenile porcine model, overlapping Absorb scaffolds showed delayed healing on histology and with OCT assessment and slower tissue coverage than nonoverlapping scaffolds. Indeed, the neoendothelial coverage of the overlapping segments was 80.1% and 99.5% at 28 and 90 days after implantation, respectively; accordingly, coverage in humans may need up to 18 months to be completed (16) . Among the 62 patients with MACE, Table 2 .
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